US Representative

Christopher Smith 2023-2024 Regular Session - Authored & Sponsored Legislation (Page 10)

Legislative Session

Co-Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3693

Introduced
5/25/23  
Migrant Relocation Transparency Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3702

Introduced
5/25/23  
Access Technology Affordability Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB371

Introduced
1/17/23  
Refer
1/17/23  
Defund Planned Parenthood Act of 2023 This bill restricts federal funding for Planned Parenthood Federation of America Inc. or any of its affiliates or clinics for one year. Specifically, it prohibits funding those entities unless they certify that the affiliates and clinics will not perform, and will not provide funds to entities that perform, abortions during that year. If the certification requirement is not met, the Department of Health and Human Services and the Department of Agriculture must recoup any federal assistance received by those entities. However, the bill's funding restriction does not apply to abortions performed in cases of rape or incest or when necessary to resolve a physical condition that endangers a woman's life. The bill also provides additional funding for community health centers for the one-year period. These funds are subject to the same abortion-related restrictions and exceptions.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB372

Introduced
1/17/23  
Refer
1/17/23  
Protecting Life and Taxpayers Act of 2023 This bill requires federally funded entities to certify that they will not, subject to certain exceptions, perform abortions or provide funding to other entities that perform abortions. The bill provides exceptions for abortions (1) in cases of rape or incest; or (2) when the life of the woman is in danger due to a physical disorder, injury, or illness.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3773

Introduced
5/31/23  
Stop Anti-Semitism on College Campuses Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3774

Introduced
5/31/23  
Refer
5/31/23  
Report Pass
10/19/23  
SHIP Act Stop Harboring Iranian Petroleum Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3782

Introduced
6/1/23  
Refer
6/1/23  
Short Line Railroad Relief Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3792

Introduced
6/1/23  
U.S.-Israel Partnership and Abraham Accords Enhancement Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB382

Introduced
1/17/23  
Refer
1/17/23  
Refer
1/27/23  
Pandemic is Over Act This bill terminates the COVID-19 public health emergency that was declared on January 31, 2020, on the date of the bill's enactment.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3821

Introduced
6/5/23  
Refer
6/5/23  
Refer
6/9/23  
Report Pass
7/19/23  
Firefighter Cancer Registry Reauthorization Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB383

Introduced
1/17/23  
Refer
1/17/23  
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3867

Introduced
6/6/23  
Refer
6/6/23  
Spotted Lanternfly Research and Development Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3888

Introduced
6/7/23  
Refer
6/7/23  
To amend title 38, United States Code, to strengthen benefits for children of Vietnam veterans born with spina bifida, and for other purposes.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3894

Introduced
6/7/23  
Refer
6/7/23  
Greyhound Protection Act of 2023

Primary Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3827

Introduced
6/5/23  
Refer
6/5/23  
Protect Our Workers Act of 2023